pharmaceutical

Lenz Therapeutics stock plummeted 11.2% after Q4 earnings miss, larger-than-expected losses, and disappointing VIZZ prescription uptake despite strong pipeline projections.

Ridgetech shares fell 23.74% to $2.73 in premarket trading Tuesday amid broader market weakness and concerns about its 2026 growth strategy execution.

Eli Lilly discontinuing select insulin products across EU/EEA by Q2 2027 due to commercial factors. Company's experimental retatrutide shows strong diabetes and weight-loss results.

Bristol Myers Squibb's attractive 4.4% dividend yield faces headwinds from major patent expirations on blockbuster drugs Eliquis and Opdivo.

AbbVie stock down 11% YTD but trades at 14x forward P/E with 0.49 PEG, suggesting undervaluation amid strong new drug momentum and 3.4% dividend yield.

Eli Lilly awaits April 10 FDA decision on oral weight loss drug orforglipron, amid $11B quarterly sales from current portfolio. Approval could catalyze gains, but long-term fundamentals matter more than short-term decisions.

Sio Capital Management invested $24.53 million in Organon ($OGN) at $6.03/share, betting on turnaround potential despite 61% annual decline. Company maintains flat 2026 guidance with $1.9B adjusted EBITDA.

Portnoy Law Firm files class action against $AQST for allegedly misleading investors about Anaphylm FDA prospects. Stock plunged 37% after deficiency disclosure.

Portnoy Law Firm investigates Novo Nordisk for possible securities fraud after CagriSema obesity drug failed trial, triggering 16.43% stock decline.

AbbVie, Walmart, and Consolidated Edison emerge as top dividend plays for March 2026, each boasting 50+ years of consecutive dividend increases.

Ipsen withdraws Tazverik globally and appoints Michelle C. Werner as North America president, signaling strategic portfolio optimization and leadership strengthening.

SciSparc's NeuroThera Labs acquires 54% of quantum clinical trials company CliniQuantum for $9.46M in stock plus $2.5M earn-out, closing by March 2026.

AbbVie reports Phase 1 data for obesity treatment ABBV-295, showing 7.75%-9.79% weight loss. Stock declined despite positive results amid broader market pressure.

Novo Nordisk leads GLP-1 market but faces Eli Lilly competition; Amgen's MariTide offers differentiated approach with less portfolio risk.

Johnson & Johnson and Zoetis identified as premier dividend stocks for income investors, citing consistent growth, innovation pipelines, and demographic tailwinds.

Lisata Therapeutics agreed to be acquired by Kuva Labs for $5.00 per share plus up to $1.00 contingent payment, closing expected in Q2 2026.

Lisata Therapeutics agrees to be acquired by Kuva Labs for $5 per share plus up to $1 contingent payment tied to FDA approval, with close expected in Q2 2026.

Impact Biomedical shares surge 86% after SEC filing extends merger with Dr Ashley's Bio Labs to July 2026 and restructures equity allocation.

Analysts spotlight $LLY's obesity drug dominance and $VEEV's cloud expansion as top growth picks for first half 2026.

Regeneron's Dupixent dominance and deep pipeline across weight management, oncology, and rare diseases position the company for sustained growth through the mid-2030s.